Cyclooxygenase 1
-
Subject Areas on Research
- Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide.
- Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1beta.
- Aspirin resistance.
- Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
- COX-2 inhibitors.
- Coupling of COX-1 to mPGES1 for prostaglandin E2 biosynthesis in the murine mammary gland.
- Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning.
- Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition.
- Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.
- Diagnostics for aspirin resistance.
- Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
- Genetic Variants in Cyclooxygenase-2 Contribute to Post-treatment Pain among Endodontic Patients.
- Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
- Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib.
- Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam.
- Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis.
- Nitric oxide synthase-2 induction optimizes cardiac mitochondrial biogenesis after endotoxemia.
- Pyridazinones as selective cyclooxygenase-2 inhibitors.
- Reduced spontaneous relaxation in immature guinea pig airway smooth muscle is associated with increased prostanoid release.
- Reduction of spinal PGE2 concentrations prevents swim stress-induced thermal hyperalgesia.
- Role for thromboxane receptors in angiotensin-II-induced hypertension.
- Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).
- The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
- Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.